First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice

International Journal of Pharmaceutics

Volumn 479, Issue 2, 2015, Pages 408-415

  Scherließ, Regina ^a   Mönckedieck, Mathias ^a   Young, Katherine ^b   Trows, Sabrina ^a   Buske, Simon ^a   Hook, Sarah ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Chitosan; Local cellular response; Microparticles; Nano in microparticle formulation; Powder insufflation

Indexed keywords

AGAROSE; CHITOSAN NANOPARTICLE; MANNITOL; NANOPARTICLE; OVALBUMIN; VACCINE; ANTIGEN; CHITOSAN; IMMUNOLOGICAL ADJUVANT; POWDER; SEPHAROSE;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TRANSFER; CELLULAR IMMUNITY; CERVICAL LYMPH NODE; CONTROLLED STUDY; DRUG FORMULATION; DRUG TOLERABILITY; DRY POWDER; EVALUATION STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMPARATIVE STUDY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; POWDER; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; MANNITOL; MICE; MICE, INBRED BALB C; NANOPARTICLES; OVALBUMIN; POWDERS; SEPHAROSE; VACCINES;

EID: 84921368847     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.01.015     Document Type: Article

References (44)

1. H.O. Alpar, J.E. Eyles, E.D. Williamson, and S. Somavarapu Intranasal vaccination against plague, tetanus and diphtheria Adv. Drug Deliv. Rev. 51 2001 173 201
2. H.O. Alpar, S. Somavarapu, K.N. Atuah, and V.W. Bramwell Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery Adv. Drug Deliv. Rev. 57 2005 411 430
3. M. Amidi, S.G. Romeijn, J.C. Verhoef, H.E. Junginger, L. Bungener, A. Huckriede, D. Crommelin, and J.A. Jiskoot N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model Vaccine 25 2007 144 153
4. J.-P. Amorij, A. Huckriede, J. Wilschut, H.W. Frijlink, and W.L.J. Hinrichs Development of stable influenza vaccine powder formulations: challenges and possibilities Pharm. Res. 25 2008 1256 1273
5. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10 2010 787 796
6. F. Blank, P. Stumbles, and C. von Garnier Opportunities and challenges of the pulmonary route for vaccination Expert Opin. Drug Deliv. 8 2011 547 563
7. W. Boonyo, H.E. Junginger, N. Waranuch, A. Polnok, and T. Pitaksuteepong Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration J Controll. Release 121 2007 168 175
8. O. Borges, A. Cordeiro-da-Silva, J. Tavares, N. Santarem, A. de Sousa, G. Borchard, and H.E. Junginger Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles Eur. J. Pharm. Biopharm. 69 2008 405 416
9. S. Buske, and R. Scherließ Nasal Deposition Analysis of a Nano-in-microparticle Vaccine Formulation in Children and Adults Using Cast Models 2013 DDL 24 Edinburgh, Scotland
10. S. Chadwick, C. Kriegel, and M.M. Amiji Nanotechnology solutions for mucosal immunization Adv. Drug Deliv. Rev. 62 2010 394 407
11. K. Chen, and A. Cerutti Vaccination strategies to promote mucosal antibody responses Immunity 33 2010 479 491
12. N. Csaba, M. Garcia-Fuentes, and M.J. Alonso Nanoparticles for nasal vaccination Adv. Drug Deliv. Rev. 61 2009 140 157
13. S.S. Davis Nasal vaccines Adv. Drug Deliv. Rev. 51 2001 21 42
14. M.-L. De Temmerman, J. Rejman, J. Demeester, D.J. Irvine, B. Gander, and S.C. De Smedt Particulate vaccines: on the quest for optimal delivery and immune response Drug Discovery Today 16 2011 569 582
15. A. Debin, R. Kravtzoff, J.V. Santiago, L. Cazales, S. Sperandio, K. Melber, Z. Janowicz, D. Betbeder, and M. Moynier Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses Vaccine 20 2002 2752 2763
16. A.M. Gallegos, and M.J. Bevan Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation J. Exp. Med. 200 2004 1039 1049
17. S. Gordon, A. Saupe, W.T. McBurney, T. Rades, and S. Hook Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery J. Pharm. Pharmacol. 60 2008 1591 1600
18. B. Haneberg, and J. Holst Can nonliving nasal vaccines be made to work? Expert Rev. Vaccines 1 2002 227 232
19. J. Holmgren, C. Czerkinsky, K. Eriksson, and A. Mharandi Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges Vaccine 21 2003 S2/89 S82/95
20. L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A.N. Fisher, and S.S. Davis Chitosan as a novel nasal delivery system for vaccines Adv. Drug Deliv. Rev. 51 2001 81 96
21. L.B. Lawson, E.B. Norton, and J.D. Clements Defending the mucosa: adjuvant and carrier formulations for mucosal immunity Curr. Opin. Immunol. 23 2011 414 420
22. X. Li, B.R. Sloat, N. Yanasarn, and Z. Cui Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design Eur. J. Pharm. Biopharm. 78 2011 107 116
23. N. Lycke Recent progress in mucosal vaccine development: potential and limitations Nat. Rev. Immunol. 12 2012 592 605
24. W.T. McBurney, D.G. Lendemans, J. Myschik, T. Hennessy, T. Rades, and S. Hook In vivo activity of cationic immune stimulating complexes (PLUSCOMs) Vaccine 26 2008 4549 4556
25. J. Mestecky, M.W. Russell, and C.O. Elson Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179 2007 5633 5638
26. M.R. Neutra, and P.A. Kozlowski Mucosal vaccines: the promise and the challenge Nat. Rev. Immunol. 6 2006 148 158
27. S. Ohtake, R.A. Martin, L. Yee, D. Chen, D.D. Kristensen, D. Lechuga-Ballesteros, and V. Truong-Le Heat-stable measles vaccine produced by spray drying Vaccine 28 2010 1275 1284
28. C.M.S. Ribeiro, and V.E.J.C. Schijns Immunology of vaccine adjuvants G. Davies, Vaccine Adjuvants 2010 Springer Science+Business Media, LCC New York 1 14
29. S. Saraf, D. Mishra, A. Asthana, R. Jain, S. Singh, and N.K. Jain Lipid microparticles for mucosal immunization against hepatitis B Vaccine 24 2006 45 56
30. R. Scherließ In Vitro Evaluation of Dry Powder Nasal Deposition from a Single Use Nasal Device 2011 DDL 22 Edinburgh 189 192
31. R. Scherließ, and S. Buske Dry powder nanoparticulate formulations for mucosal vaccination G. Tiddy, R.B. Tan, Nanoformulation 2012 RSC Publishing Singapore 104 112
32. R. Scherließ, S. Buske, K. Young, B. Weber, T. Rades, and S. Hook In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations Vaccine 31 2013 4812 4819
33. R. Scherließ, M. Mönckedieck, K. Young, S. Trows, S. Buske, and S. Hook Evaluation of impact of nasal dry powder vaccine formulations on uptake and activation by dendritic cells R. Dalby, RDD Europe 2013 2013 Davies Health Care International Publishing Berlin 279 283
34. R. Scherließ, and S. Trows Novel formulation concept for particulate uptake of vaccines via the nasal associated lymphoid tissue Procedia Vaccinol. 4 2011 113 119
35. F.A. Sharp, D. Ruane, B. Claass, E. Creagh, J. Harris, P. Malyala, M. Singh, D.T. O'Hagan, V. Pétrilli, J. Tschopp, L.A.J. O'Neill, and E.C. Lavelle Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome Proc. Natl. Acad. Sci. U. S. A. 106 2009 870 875
36. B. Slütter, S. Bal, C. Keijzer, R. Mallants, N. Hagenaars, I. Que, E. Kaijzel, W. van Eden, P. Augustijns, C. Löwik, J. Bouwstra, F. Broere, and W. Jiskoot Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen Vaccine 28 2010 6282 6291
37. M. Tafaghodi, S.A.S. Tabassi, M.-R. Jaafaria, S.R. Zakavid, and M. Momen-Nejad Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy Int. J. Pharm. 280 2004 125 135
38. S. Trows, and R. Scherließ Preparation and characterization of dry powder agarose nano-in-microparticles for nasal vaccination R.N. Dalby, Respiratory Drug Delivery 2012 2012 Davies Healthcare International Publishing Phoenix, AZ 491 496
39. I.M. van der Lubben, G. Kersten, M.M. Fretz, C. Beuvery, J.C. Verhoef, and H.E. Junginger Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice Vaccine 21 2003 1400 1408
40. I.M. van der Lubben, J.C. Verhoef, G. Borchard, and H.E. Junginger Chitosan and its derivatives in mucosal drug and vaccine delivery Eur. J. Pharm. Sci. 14 2001 201 207
41. D. Vllasaliu, R. Exposito-Harris, A. Heras, L. Casettari, M. Garnett, L. Illum, and S. Stolnik Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution Int. J. Pharm. 400 2010 183 193
42. D.T. Vodak, D.E. Dobry, R. Falk, D. Dubose, P.J. Kuehl, R. Chand, T.R. Foubert, and B.L. Steadman Enhancing the Immune Response to Intranasal Vaccination with Norovirus VLPs-Size Matters 2012 DDL 23 Edinburgh 46 49
43. R. Westmeier Novel Formulation Concept for Nasal Deposition of Dry Powder Vaccines R.N. Dalby, Respiratory Drug Delivery 2010 2010 Davies Healthcare International Publishing Orlando, Florida 523 527
44. J.H. Wilson-Welder, M.P. Torres, M.J. Kipper, S.K. Mallapragada, M.J. Wannemuehler, and B. Narasimhan Vaccine adjuvants: current challenges and future approaches J. Pharm. Sci. 98 2009 1278 1316